Evidence map›Paper›PMID 40110113›Full record

ReviewNeuropsychiatric disease and treatment2025

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia.

Leslie Citrome, Christoph U Correll, Andrew J Cutler, Martin Dunbar, Amber R Hoberg, Craig Hopkinson, Gregory W Mattingly, James A McGrory, Bhaskar Rege, Peter J Weiden and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Leslie CitromeNew York Medical College, Valhalla, NY, USA.ORCID 0000-0002-6098-9266
Christoph U CorrellDepartment of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.ORCID 0000-0002-7254-5646
Andrew J CutlerDepartment of Psychiatry, SUNY Upstate Medical University, Syracuse, NY, USA.
Martin DunbarAlkermes, Inc, Waltham, MA, USA.
Amber R HobergWellMed Medical Management, South Texas Medical Center, San Antonio, TX, USA.
Craig HopkinsonAlkermes, Inc, Waltham, MA, USA.
Gregory W MattinglyWashington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-0234-6860
James A McGroryAlkermes, Inc, Waltham, MA, USA.ORCID 0000-0003-0906-023X
Bhaskar RegeAlkermes, Inc, Waltham, MA, USA.
Peter J WeidenRenaissance School of Medicine at Stony Brook University, Stony Brook, NY, USA.ORCID 0000-0001-5583-5871
David McDonnellAlkermes Pharma Ireland Ltd, Dublin, Ireland.ORCID 0000-0002-6400-1286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review article describes why and how aripiprazole was formulated as aripiprazole lauroxil (AL), an extended-release antipsychotic agent that is delivered via a long-acting injectable formulation, and the clinical trials investigating its use. AL was formulated as an inactive prodrug of aripiprazole using LinkeRx

Indexed as

dosingpharmacokineticsphase 3 clinical trialssafetytreatment efficacytreatment initiation

Identifiers

PMID40110113
PMCPMC11921517

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.